The cautious optimism of May and June with regards to emerging from the pandemic has shifted as we are witnessing a resurgence of cases of COVID-19 but now in the form of the delta (B.1.617.2) variant, a highly contagious SARS-CoV-2 virus strain. This coronavirus has evolved and is very different for what we were dealing with in 2020 and even just a few short months ago!
First identified in India in December, the first case diagnosed in the United States was in March but now is the dominant strain in the U.S. This variant, according to the World Health Organization (WHO) is “the fastest and fittest” of the strains we have encountered since it is the most infectious version of the COVID-19 virus to date. All viruses evolve over time and undergo changes as they spread and replicate, introducing new mutations which with this variant make it more contagious than the other virus strains, thus infecting more people. Delta spreads about twice as easily from one person to another than previous strains of the virus because it infects people with a heavier virus load, which means when they breath, more virus particles are exhaled for others to catch. Wearing a mask is critical to curb the spread of this variant. Those at greatest risk however are the unvaccinated making vaccination ever more critical but Delta also seems to be impacting younger age groups more than previous variants, possibly because of lower vaccination rates in these populations. This variant appears to cause more serious illness with 85% more hospitalizations that with the original virus in the population in 2020 and people who are infected get sicker faster than with the prior virus.
The data from vaccinated people continues to demonstrate good evidence of the safety of the available vaccines as well as their effectiveness to provide protection against the variants circulating in the United States. Some vaccinated people can get Delta in a breakthrough infection and may be contagious but virtually all hospitalizations and deaths have been seen among the unvaccinated. The CDC has recommended that everyone (including fully vaccinated individuals) wear a mask in public indoor settings to help prevent spread of Delta and protect others.
Bottom line here is to get vaccinated, wear a mask practice physical distancing and practice good hygiene to prevent severe illness, hospitalizations, and death.
The FDA has not yet approved vaccines for children younger than 12 years. Children ages 12 and older are eligible for COVID-19 vaccines in the U.S. Parents should vaccinate their children as early as possible and, if they’re not eligible for vaccination yet, continue to take precautions, such as masking and social distancing.

Please see the July 27th MMWR Report from the CDC titled “Guidance for Implementing COVID-19 Prevention Strategies in the Context of Varying Community Transmission Levels and Vaccination Coverage” for more information and for the latest recommendations, visit  
Two high profile Olympic athletes, Naomi Osaka and Simone Biles raised the curtain on mental health for all of us. Osaka talked openly about her own mental health struggles after she was eliminated from the women's Olympic tennis tournament. After winning five medals in Rio in 2016, Olympian Simone Biles prioritized her mental health over attempts to secure another medal at the 2020 Olympics currently underway in Japan. “I have to focus on my mental health,” Biles said, acknowledging that she had been struggling with the intense pressure. Mental health is an issue for all of us especially given the isolation, stress and fear that has come with the pandemic. The June 21st MMWR report from the CDC highlights that over half of surveyed public health workers reported depression, anxiety, or post-traumatic stress disorder. We are all feeling the impact of the life events unfolding around us. Resources are available from NHF and your HTC when needed. Like Osaka and Biles, reach out and let others know when you feel stressed, anxious, or fearful.

Four Decades of HIV

This June marked a significant milestone for the bleeding disorders community. Forty years ago, on June 5, 1981, the CDC first reported a rare cancer found in five homosexual men in their Mortality and Morbidity Weekly Report. These were the first reported cases of what would come to be known as the Human Immunodeficiency Virus (HIV). In early 1982, the first case of HIV was found in a child with hemophilia. HIV was present in most of the available products used at the time. Patients were unknowingly being infected by the very treatment used to improve their health and well being. Over the course of the next few years, the community experienced devastating losses. In total, 5,000 hemophilia patients were infected with HIV, and about 4,000 died tragically before changes were made to ensure products to treat bleeding disorders were made safe.

Today, about 1.2 million Americans live with HIV, an globally that number is quickly approaching 38 million. While effective prevention and treatment options do now exist, they are not available everywhere in the world where patients are at greater risk. As we commemorate 40 years of living with HIV as a society, we remind ourselves that we can learn from the years of loss and devastation. While HIV is no longer an absolute death sentence, we understand the need to address health disparities, stigma, and unequal distribution of resources that have plagued the way we care for all people at risk of and living with HIV.

TARPA-H Overview

TARPA-H Overview

President Biden has called for the creation of a new $6.5 billion research institute, the Advanced Research Projects Agency for Health (ARPA-H), to speed innovation and lead to cures for critical diseases. If created, ARPA-H could benefit the inherited bleeding disorders community both directly – through projects specifically targeted at our community – or indirectly, such as through research that accelerates development of gene therapies or improves drug development and delivery more generally.

In a recent commentary published in Science, NIH Director Dr. Francis Collins and White House Office of Science and Technology Policy Director Dr. Eric Lander described ARPA-H as combining the health expertise of the NIH with the culture and speed of the Defense Advanced Research Projects Agency (DARPA) to tackle time-limited projects to revolutionize how diseases are prevented, treated and ultimately cured.  For the past 60 years, DARPA has taken on high-risk projects without being worried about failure, which have led to some amazing advances, including the creation of the internet.  ARPA-H would follow the same model to address bold, high-risk problems and remove barriers to transform health and medicine, so patients receive better treatments and cures more equitably and quickly than today.

While the proposal was included in President Biden’s budget for Fiscal Year 2022, Congress will ultimately decide whether and where ARPA-H would be created, as well as at what funding level. A bipartisan group of Congressional leaders has expressed support for the proposal and there has been discussion of creating ARPA-H both via the regular appropriations process, as well as through stand-alone legislation.  NHF is closely monitoring all of this activity and will continue its advocacy in support of clinical research that benefits the bleeding disorders community.

Copyright © 2021 National Hemophilia Foundation, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.